July 27, 2020 / 11:03 AM / 11 days ago

Moderna's COVID-19 vaccine candidate moves into late-stage trial

July 27 (Reuters) - Moderna Inc said on Monday it has started a U.S. government-backed late-stage trial evaluating its COVID-19 vaccine candidate, mRNA-1273, in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.

The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below